Residency · Residency · Chronic Pain Management

Antidepressants for Chronic Pain: SNRIs and TCAs

Introduction

Antidepressants are among the most evidence-based pharmacological treatments for chronic pain, particularly neuropathic pain syndromes. Their analgesic effects are independent of their antidepressant properties — they occur at lower doses and with faster onset than mood effects. The two classes with the strongest evidence are serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs). Understanding their mechanisms, efficacy data, dosing strategies, and safety profiles is essential for effective chronic pain management.

Mechanisms of Analgesic Action

The primary analgesic mechanism of both SNRIs and TCAs involves enhancement of descending inhibitory pain pathways that originate in the periaqueductal gray (PAG), locus coeruleus, and rostral ventromedial medulla (RVM). Norepinephrine reuptake inhibition activates alpha-2 adrenergic receptors in the spinal dorsal horn, directly inhibiting pain transmission — and this is the dominant analgesic mechanism. Serotonin reuptake inhibition contributes via 5-HT receptor subtypes in the descending pathways, though the role of serotonin is more complex because some subtypes are actually pronociceptive.

TCAs bring additional analgesic mechanisms beyond monoamine reuptake inhibition. They block sodium channels in a manner similar to local anesthetics, antagonize NMDA receptors, and block histamine and muscarinic receptors (the latter contributing to sedation, which can benefit sleep). The fact that analgesic potency correlates more strongly with norepinephrine reuptake inhibition than with serotonin reuptake inhibition explains why SSRIs are largely ineffective for neuropathic pain.

<image>Neuroanatomical illustration of the descending pain modulatory system showing the pathway from cortex to periaqueductal gray to rostral ventromedial medulla to spinal dorsal horn, with labeled neurotransmitter release points for serotonin and norepinephrine, and markers showing where SNRIs and TCAs act to enhance inhibitory signaling at the dorsal horn synapse</image>

SNRIs: Duloxetine and Venlafaxine

Duloxetine

Duloxetine is FDA-approved for diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain, and osteoarthritis, making it the only SNRI with multiple FDA-approved pain indications. It provides balanced serotonin and norepinephrine reuptake inhibition at therapeutic doses, with a number needed to treat (NNT) for neuropathic pain of approximately 6.4.

Dosing begins at 30 mg daily for one week, then increases to 60 mg daily — the target analgesic dose. Doses above 60 mg rarely provide additional pain benefit. Onset of analgesic effect is typically 1-2 weeks, with full effect by 4-8 weeks. Duloxetine is metabolized via CYP1A2 and CYP2D6 and should be avoided in severe hepatic impairment. The most common adverse effects are nausea (usually transient), dry mouth, constipation, dizziness, somnolence, and hyperhidrosis.

Venlafaxine

Venlafaxine is not FDA-approved for pain but has evidence supporting its use in neuropathic pain and migraine prophylaxis. A critical prescribing point is that at low doses (below 150 mg), venlafaxine is primarily a serotonin reuptake inhibitor — norepinephrine reuptake inhibition only becomes significant at doses of 150 mg per day or higher. This means analgesic dosing is typically 150-225 mg per day, using the extended-release formulation.

The NNT for neuropathic pain is approximately 6.4, comparable to duloxetine. Blood pressure should be monitored at higher doses because of dose-dependent hypertension. Venlafaxine also carries a higher discontinuation syndrome risk compared to duloxetine, so gradual tapering is essential.

TCAs: Amitriptyline and Nortriptyline

Amitriptyline

Amitriptyline is the most extensively studied antidepressant for chronic pain, with an NNT for neuropathic pain of approximately 3.6 — among the lowest of any neuropathic pain medication. Analgesic doses are typically 25-75 mg at bedtime, substantially lower than the antidepressant doses of 150-300 mg.

As a tertiary amine TCA, amitriptyline provides potent serotonin and norepinephrine reuptake inhibition along with significant anticholinergic, antihistaminic, and alpha-adrenergic blockade. For some patients, the side effect profile is actually beneficial: sedation aids sleep, and appetite stimulation may be welcome. However, the overall side effect burden limits tolerability, especially in elderly patients.

Nortriptyline

Nortriptyline is the active metabolite of amitriptyline and belongs to the secondary amine TCA subclass. It is more selective for norepinephrine reuptake inhibition and is better tolerated than amitriptyline, with fewer anticholinergic and sedative effects. Head-to-head trials show comparable analgesic efficacy, making nortriptyline the preferred TCA in elderly patients and those sensitive to anticholinergic effects. Dosing starts at 10-25 mg at bedtime and is titrated to 75-150 mg as tolerated.

<image>Comparison table rendered as a detailed infographic showing duloxetine, venlafaxine, amitriptyline, and nortriptyline side by side, with receptor binding affinity profiles displayed as horizontal bar charts for SERT, NET, muscarinic, histaminic H1, and alpha-1 adrenergic receptors, along with NNT values, FDA-approved pain indications, and common adverse effects listed below each medication</image>

NNT Data and Comparative Efficacy

The efficacy hierarchy is worth knowing clearly. TCAs (amitriptyline) have the strongest NNT at approximately 3.6 for neuropathic pain. SNRIs (duloxetine) follow at approximately 6.4. SSRIs are not significantly different from placebo for neuropathic pain and are generally ineffective. For fibromyalgia, duloxetine has an NNT of approximately 8, while amitriptyline performs better at approximately 4.3. For diabetic neuropathy, duloxetine and TCAs show comparable efficacy. For postherpetic neuralgia, TCAs have stronger evidence than SNRIs.

The number needed to harm (NNH) for TCAs is approximately 13 for major adverse effects, with lower thresholds for minor effects. This means the superior NNT of TCAs must always be weighed against their worse safety profile, particularly their cardiac risks.

Dosing Strategies

The "start low, go slow" principle is particularly important for TCAs in elderly patients. TCA initiation should begin at 10 mg at bedtime in elderly patients or 25 mg at bedtime in younger adults, titrating by 10-25 mg increments every 1-2 weeks. Administering TCAs at bedtime leverages their sedative effects and minimizes daytime drowsiness. SNRI titration is generally faster — duloxetine can reach its target dose in 1-2 weeks.

Therapeutic drug monitoring for TCAs targets serum levels of 80-120 ng/mL for amitriptyline (combined with its nortriptyline metabolite). Regardless of the agent chosen, an adequate trial duration of at least 6-8 weeks at therapeutic dose is necessary before deeming treatment a failure.

Adverse Effect Management

TCA-Specific Concerns

Cardiac toxicity is the most serious risk: TCAs can cause QT prolongation and conduction delays, making a baseline ECG essential. They are contraindicated in patients with bundle branch block or recent myocardial infarction. Anticholinergic effects — dry mouth, constipation, urinary retention, blurred vision, and cognitive impairment — can be minimized by choosing nortriptyline over amitriptyline. Orthostatic hypotension from alpha-1 adrenergic blockade is particularly problematic in elderly patients. Weight gain from the antihistaminic effect requires monitoring of metabolic parameters. TCAs are lethal in overdose — as few as one to two weeks' supply can be fatal — so prescribing limited quantities is essential in patients with suicidal ideation.

SNRI-Specific Concerns

Serotonin syndrome is a risk when SNRIs are combined with other serotonergic agents such as tramadol, triptans, or MAOIs. Hypertension is dose-dependent and more common with venlafaxine, necessitating blood pressure monitoring. Discontinuation syndrome requires tapering over a minimum of 2-4 weeks, with venlafaxine XR being particularly problematic. Sexual dysfunction is common with both duloxetine and venlafaxine. Hepatotoxicity is rare but reported with duloxetine, and the drug should be avoided in pre-existing liver disease.

<image>Safety monitoring checklist formatted as a clinical pocket card, listing baseline assessments before starting TCAs (ECG, vital signs, hepatic and renal function, falls risk assessment) and SNRIs (blood pressure, hepatic function), with recommended follow-up monitoring intervals at 2 weeks, 1 month, 3 months, and ongoing, specifying which parameters to check at each time point</image>

Clinical Pearls

Nortriptyline is the preferred TCA for most chronic pain patients due to comparable efficacy with better tolerability than amitriptyline. The analgesic effect of antidepressants is independent of mood effects, and patients should be counseled that these medications are being prescribed specifically for pain. Duloxetine is generally first-line among antidepressants for chronic pain due to its safety profile and multiple FDA-approved pain indications. Venlafaxine requires doses of 150 mg per day or higher to achieve meaningful norepinephrine reuptake inhibition for analgesia. TCAs are the most cost-effective option for neuropathic pain but must be used cautiously in elderly patients — the Beers Criteria lists amitriptyline as potentially inappropriate in this population. Antidepressants should always be tapered gradually to avoid discontinuation syndrome and should never be stopped abruptly.

References

1. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.
2. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;(7):CD008242.
3. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;(1):CD007115.
4. Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for neuropathic pain in adults. Cochrane Database Syst Rev. 2012;(3):CD011789.

Read this lecture as Markdown